GRI-0621 an oral, RARβ/γ-selective investigational therapy designed to modulate pathways involved in inflammation and fibrosis in IPF. Emerging scientific evidence increasingly supports the role of ...

GRI Bio ( (GRI)) has issued an announcement. On May 14, 2026, GRI Bio reported first-quarter 2026 results and new Phase 2a data showing its IPF candidate GRI-0621 improved key clinical symptoms and ...

The Global Reporting Initiative is responding to a proposal from the International Financial Reporting Standards Foundation to oversee sustainability standards alongside international accounting ...

GRI Bio, Inc. has received a recommendation from the Independent Data Monitoring Committee to continue its Phase 2a study of GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF) following ...

More companies in Italy will be supported to disclose their impacts using the world’s leading sustainability reporting framework, following Italian becoming the latest translation of the GRI Standards ...

GRI Bio, Inc. has announced expected interim and topline data readouts from its Phase 2a biomarker study for the lead program GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF), in Q2 and ...

The International Financial Reporting Standards Foundation and the Global Reporting Initiative said Thursday they have reached a collaboration agreement to coordinate their standard-setting and work ...

Short interest in GRI Bio Inc (NASDAQ:GRI) increased during the last reporting period, rising from 142.33K to 383.63K. This put 6.53% of the company's publicly available shares short. Based on the ...

The revision came at an unprecedented time. The COVID-19 pandemic highlighted many gaps in understanding the impact of our supply chains on social structures and communities; revealing deep inequities ...